Latest Content

COVID-19-related Medicare spending and health care use declined after acute infection, with minimal excess costs by weeks 13 to 40 after diagnosis.

Explore the biggest FDA PDUFA decisions expected in 2026, including gedatolisib, iberdomide, zidesamtinib, bepirovirsen, and anito-cel.

Financial toxicity in pediatric cancer extends beyond medical bills, affecting treatment adherence, caregivers, and survivors long-term, Cherie Daly, MD, said.

Benchmarking and interoperability reveal outlier utilization early, helping health leaders prevent fraud, waste, and abuse while strengthening compliance and value-based performance.

Expanded FDA indications and Medicare coverage of semaglutide for cardiovascular risk prevention were associated with increased Wegovy utilization, most notably through Medicare Part D.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

As prescription drug affordability boards move toward upper payment limit implementation, uncertainties introduced across the health care system and risks to patient access warrant urgent attention.

The expanded approval, based on the phase 3 WIL-33 trial, gives children with von Willebrand disease access to routine bleeding prophylaxis.

Large biobank study suggests a polygenic risk score may improve prediction of idiopathic pulmonary fibrosis diagnosis and outcomes.